R. Donald Harvey
0000-0002-4217-1313
158 papers found
Refreshing results…
Science of Biosimilars
Abstract CT032: A Phase 1b study of PEGPH20 plus pembrolizumab in patients with selected hyaluronan-high solid tumors
A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction
GCT1021-01, a first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors (NCT02988817).
Enrollment into molecular selection trials and impact on patient disposition.
A phase I study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients (pts) with advanced solid tumors.
Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling
Phase I/Ib Pharmacokinetics and Safety Study of Ixazomib in Multiple Myeloma Patients With Severe Renal Impairment/End-Stage Renal Disease Requiring Hemodialysis (Esrd)
P3. 02c-011 A Phase 1b Open-Label Study of PEGPH20 Combined with Pembrolizumab in Patients with Selected Hyaluronan-High Solid Tumors: Topic: Targeted Therapy
Preventing and Managing Toxicities of High-Dose Methotrexate
Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors
Investigational NEDD8-activating enzyme inhibitor pevonedistat (Pev) plus chemotherapy in patients (Pts) with solid tumors (Phase 1b study): Antitumor activity of pev plus carboplatin (Carbo)/paclitaxel (Pac).
Effect of itraconazole or rifampicin on the pharmacokinetics (PK) of osimertinib (AZD9291).
Effect of multiple-dose osimertinib (AZD9291) on the pharmacokinetics (PK) of simvastatin and rosuvastatin.
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis
Calcium and Cancer: Of Evil Humors and Innocent Bystanders
Impact of Isotope Dilution Mass Spectrometry (IDMS) Standardization on Carboplatin Dose and Adverse Events
Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors
Global population pharmacokinetic (PK) analysis of ixazomib, an oral proteasome inhibitor, including data from the phase 3 TOURMALINE-MM1 study: an application of model based analysis to influence posology decisions in oncology drug development
A Phase I Study of Oprozomib to Assess Drug-Drug Interaction With Midazolam in Patients With Advanced Malignancies.
Missing publications? Search for publications with a matching author name.